Draft:Mustang Bio

Nurix Therapeutics Announces Formation of DeCART Therapeutics to Advance New CAR T Therapies Using Targeted Protein Modulation

Retrieved on: 
Thursday, June 25, 2020
Medicine, Clinical medicine, Health sciences, Cancer treatments, Virotherapy, Immunotherapy, Adoptive cell transfer, Therapy, Draft:Mustang Bio, Cancer immunotherapy

SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.

Key Points: 
  • SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.
  • Dr. June will lead the DeCART founding team and also serve as the chairman of DeCARTs scientific advisory board.
  • DeCART will explore development and commercialization of CAR T cell therapies for both hematologic and solid tumors.
  • DeCART expects to combine the power of Nurixs protein modulation technologies with novel CAR T therapies to address current immunotherapy limitations and improve outcomes for patients with cancer.

Mustang Bio Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, June 10, 2020
Cars, Car body styles, Initial public offering, Prospectus, Public offering, Ford Mustang, Draft:Mustang Bio

Mustang expects to grant the underwriters a 30day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.

Key Points: 
  • Mustang expects to grant the underwriters a 30day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.
  • All of the shares of common stock are being offered by the Company.
  • A final prospectus supplement to the base prospectus describing the terms of the offering will be filed with the SEC.
  • Mustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.

Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

Retrieved on: 
Tuesday, May 12, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Bioethics, Gene therapy, Molecular biology, Draft:Mustang Bio, Chimeric antigen receptor T cell

We commend them on their poster presentations at ASGCT and look forward to learning more as they continue their research to optimize our clinical trials.

Key Points: 
  • We commend them on their poster presentations at ASGCT and look forward to learning more as they continue their research to optimize our clinical trials.
  • Finally, MB-104 can induce potent anti-tumor cell lysis and proliferates in response to tumor cells but not primary T cells expressing CS1.
  • Mustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.
  • Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID.

Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, May 11, 2020
Cars, Car body styles, Coupés, Convertibles, Hatchbacks, Ford Mustang, Fender Mustang, Draft:Mustang Bio

WORCESTER, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2020.

Key Points: 
  • WORCESTER, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2020.
  • Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, We were pleased to announce several important milestones in the first few months of 2020.
  • In April 2020, Mustang announced that the EMA granted ATMP classification to MB-107 for the treatment of XSCID.
  • Research and development expenses from license acquisitions totaled $0.3 million for the first quarter of 2020, compared to $0.5 million for the first quarter of 2019.

Cell and Gene Therapies a $3.8BN Market Despite COVID-19 Crisis, Report Says

Retrieved on: 
Friday, May 8, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cancer treatments, Emerging technologies, Stem cells, Cell biology, Chimeric antigen receptor T cell, Gene therapy, Draft:Mustang Bio, Stem-cell therapy

ARLINGTON, Va., May 8, 2020 /PRNewswire/ -- Cell therapies involvethe modification of human cells which are used to replace or repair damaged tissues or cells.

Key Points: 
  • ARLINGTON, Va., May 8, 2020 /PRNewswire/ -- Cell therapies involvethe modification of human cells which are used to replace or repair damaged tissues or cells.
  • Two areas with growing development and commercialization include chimeric antigen receptor (CAR)-T therapies and stem cell therapies.
  • According to a recent report from Kalorama Information , the global market for cell and gene therapy in 2020 is estimated to reach $3,866 million.
  • Despite these efforts, the majority of the market currently is and is expected to represent treatments for cancer.

Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

Retrieved on: 
Wednesday, January 22, 2020
Draft:Mustang Bio

The conference is being held January 21 24, 2020, at the Hyatt Regency Hotel in Miami, Florida.

Key Points: 
  • The conference is being held January 21 24, 2020, at the Hyatt Regency Hotel in Miami, Florida.
  • Mustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.
  • Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market.
  • Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission.

Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

Retrieved on: 
Monday, December 2, 2019
Life sciences, Articles, Biotechnology, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Draft:Mustang Bio

The conference will be held at the Four Seasons Hotel in Boston, Massachusetts.

Key Points: 
  • The conference will be held at the Four Seasons Hotel in Boston, Massachusetts.
  • Mustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.
  • Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market.
  • Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission.